Mayo Clinic News Network
JACKSONVILLE, Fla. — The U.S. Food and Drug Administration (FDA) has agreed to allow Mayo Clinic to use an automated bioreactor-based stem cell production platform on its campus in Jacksonville, Florida. This enables the Mayo Clinic Center for Regenerative Medicine to produce cells from the bone marrow of a stem cell donor in quantities large enough to make several doses that can be used as treatments in clinical trials.
Continue reading the full article atMayo Clinic News Network
Helpful links
- Explore Mayo's Center for Regenerative Medicine
Hello @mayoclinicchestsurgeryteam, This is great news for many who have hopes of one day being able to receive stem cell treatment in hope of one day providing a healing process for incurable diseases. Thanks Mayo Clinic!!!!